These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10877374)

  • 21. [Alpha-2 adrenergic agonists in the treatment of glaucoma].
    Apătăchioae I; Chiseliţă D
    Oftalmologia; 1999; 47(2):35-40. PubMed ID: 10641099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The benefit of scratch patch testing to demonstrate ocular contact allergy to brimonidine tartrate.
    Ringuet J; Lajoie C; Bourgault S; Simonyan D; Houle MC
    Contact Dermatitis; 2022 Oct; 87(4):336-342. PubMed ID: 35642327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
    Maus TL; Nau C; Brubaker RF
    Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
    Yuen NS; Cheung P; Hui SP
    Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
    Motolko MA
    Curr Med Res Opin; 2008 Sep; 24(9):2663-7. PubMed ID: 18691444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical experience with apraclonidine 0.5%.
    Gross RL; Pinyero A; Orengo-Nania S
    J Glaucoma; 1997 Oct; 6(5):298-302. PubMed ID: 9327348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allergic contact dermatitis from apraclonidine.
    Armisen M; Vidal C; Quintans R; Suarez A; Castroviejo M
    Contact Dermatitis; 1998 Oct; 39(4):193. PubMed ID: 9817226
    [No Abstract]   [Full Text] [Related]  

  • 28. Brimonidine and apraclonidine as vasoconstrictors in adjustable strabismus surgery.
    Dahlmann-Noor AH; Cosgrave E; Lowe S; Bailly M; Vivian AJ
    J AAPOS; 2009 Apr; 13(2):123-6. PubMed ID: 19393510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selectivity of site of action and systemic effects of topical alpha agonists.
    Robin AL; Burnstein Y
    Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term efficacy of apraclonidine hydrochloride added to maximum-tolerated medical therapy for glaucoma. Apraclonidine Maximum-Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin DH; Smythe B; Mundorf T; Lehmann RP
    Am J Ophthalmol; 1995 Oct; 120(4):423-32. PubMed ID: 7573299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
    Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
    Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.
    Robin AL; Ritch R; Shin D; Smythe B; Mundorf T; Lehmann RP
    Trans Am Ophthalmol Soc; 1995; 93():421-38; discussion 439-41. PubMed ID: 8719690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of adrenergic agonist induced allergy bioactivation and antigen formation.
    Thompson CD; Macdonald TL; Garst ME; Wiese A; Munk SA
    Exp Eye Res; 1997 May; 64(5):767-73. PubMed ID: 9245907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
    Carrasco MA; Schlaen BA; Zárate JO
    Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Gebhardt DO
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):275. PubMed ID: 10086159
    [No Abstract]   [Full Text] [Related]  

  • 37. [Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
    Hoyng PF; Rasker MT
    Ned Tijdschr Geneeskd; 1998 Sep; 142(39):2138-41. PubMed ID: 9856229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
    thoe Schwartzenberg GW; Buys YM
    Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
    Lee JS; Kim CY
    Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alphagan allergy may increase the propensity for multiple eye-drop allergy.
    Osborne SA; Montgomery DM; Morris D; McKay IC
    Eye (Lond); 2005 Feb; 19(2):129-37. PubMed ID: 15254495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.